According to the announcement of the independent British agency Nicholas Hall, specialised for the analysis of market indicators for OTC products, JGL’s brand Dramina was named the best-selling product for 2014 in the category of prevention of motion sickness, in the region of Central and Eastern Europe, where it convincingly holds an impressive 20 percent of market share.
With an annual sale of over 3.5 million product units, Dramina is one of the three most successful JGL brands, immediately after Aqua Maris and Lactogyn.
Immediately after its launch in 1995, Dramina positioned itself as one of the most successful JGL’s products. It is present on 16 markets, with a special emphasis on the Croatian market, and JGL’s biggest market, that of Russia, where the brand has been a leader for years with over 80 percent of market share per individual market.
Motion sickness, travel sickness, sea sickness, or “kinetosis” in professional terms, is manifested by unpleasant symptoms such as dizziness, fatigue, nausea and vomiting. It affects all age groups and women tend to suffer from it more often than men. For a number of years, an antihistamine called dimenhydrinate, an active component of Dramina, has been recommended as the first choice of treatment for people suffering from travel sickness. Dramina experienced its global success in the same year as the twentieth anniversary of its market launch.